Cullinan Oncology & MABD Enter Collaboration

Cullinan Oncology and MAB Discovery GmbH (MABD), announced the initiation of a collaboration to develop novel antibody therapeutics based on MABD’s unique discovery platform.

“We are excited to enter into this collaboration as the MABD development engine provides us with access to highly differentiated monoclonal antibodies” said Patrick Baeuerle, Cullinan’s chief scientific officer, Biologics. “Our first program is a novel agonistic antibody that has the potential to be a pillar of future immuno-oncology and standard treatments. We look forward to working with Stephan Fischer and the MABD team to execute the development plan and progress the asset into the clinic.”

Under the terms of the agreement, MABD has the potential to receive cash payments upon the achievement of various milestones in addition to an upfront equity interest in Cullinan Wittelsbach, a subsidiary of Cullinan Oncology LLC formed to fund and shepherd the development of the asset.